tbuckley/cabot-search huggingface dataset:
Abstract 877: Detection of colorectal cancer-associated genetic alterations in urine of patients with CRC
Authors: Adam W. Clemens, Selena Lin, Surbhi Jain, Sitong Chen, Ying-Hsiu Su, Wei Song
Journal: Cancer Research (2014)

Abstract Colorectal cancer (CRC) has been the second leading cause of cancer-related deaths due in part to a low compliance rate (&amp;lt;50%) of the current screening method, an invasive colonoscopy, resulting in failure of detecting cancer early in its curative stages. 20% of CRCs are only detected once the cancer has spread to a distant site, drastically reducing the 5-year survival rate from 90% to 12%. In order to improve the success of early detection methods of CRC, we have focused on developing non-invasive, multi-biomarker detection assays designed to identify CRC-associated genetic alterations. The genetic alterations of four genes, (mutations of the KRAS (muKras) and BRAF V600E (muBRAF) genes and aberrant hypermethylation of the Vimentin (mVIM) and Septin9 (mSEPT9) genes, have shown to be potential biomarkers of CRC through stool or serum-derived DNA. We set out to show that these four biomarkers could be used as a panel for a non-invasive urine test of CRC in a highly specific and sensitive manner. We have previously demonstrated that urine contains circulation-derived low molecular weight (LMW) DNA (&amp;lt;300 bp), which suggests that LMW urine DNA could be used to detect CRC-associated genetic alterations. A blinded concordance study was used to validate mVIM as a biomarker for CRC between 20 urine samples and the corresponding tissue sample. We have developed a locked nucleic acid (LNA) clamp and a Simple Probe to distinguish mVIM from normal VIM suitable for fragmented short DNA templates. By using this assay, we indicated that mVIM can be detected from LMW urine DNA, and it has the potential to serve as a CRC-specific biomarker (Song et al., 2012). This LNA-clamp short-qPCR assay has been adapted for quantitation of muBRAF, muKRAS, and mSEPT9, for testing these biomarkers with open-labeled CRC samples. In addition, a prevalidation study is in progress with blinded CRC samples to confirm the specificity and sensitivity of these genetic biomarkers. References Song, B. P., Jain, S., Lin, S. Y., Chen, Q., Block, T. M., Song, W., ... &amp; Su, Y. H. (2012). Detection of hypermethylated vimentin in urine of patients with colorectal cancer. The Journal of Molecular Diagnostics, 14(2), 112-119. Citation Format: Adam W. Clemens, Selena Lin, Surbhi Jain, Sitong Chen, Ying-Hsiu Su, Wei Song. Detection of colorectal cancer-associated genetic alterations in urine of patients with CRC. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 877. doi:10.1158/1538-7445.AM2014-877
Abstract 17793: Mutation of Anti-aging Gene Klotho Causes Hypertension via Upregulation of CYP11B2 Expression and Aldosterone Syhthesis
Authors: Xiaoli Zhou, Yongjun Wang, Han Lei, Zhongjie Sun
Journal: Circulation (2014)

Background: Klotho (KL) is a recently discovered anti-aging gene. Genetic mutation of KL expedites the aging process and shortens lifespan while overexpression of KL slows down the aging process and extends lifespan. The purpose of this study is to assess how KL deficiency may affect blood pressure (BP). Methods & Results: Heterozygeous KL mutant mice (+/-) showed spontaneous and persistent elevation of BP, indicating that KL is essential to the maintenance of normal BP. Plasma level of aldosterone was increased which concurred with elevation of BP in KL(+/-) mice. Blockade of aldosterone actions by eplerenone (6 mg/kg/day, IP) decreased BP of KL(+/-) mice to the control level and attenuated kidney damage, suggesting that upregulation of aldosterone synthesis is responsible for KL deficiency-induced hypertension. Protein expression of CYP11B2, a key enzyme for aldosterone synthesis, was upregulated in adrenal cortex of KL(+/-) mice. The immunofluorescence analysis showed that klotho and CYP11B2 protein we...
Abstract 2840: Evaluation of HER-2 RNA and protein levels in a large cohort of breast cancer specimens to support development of a diagnostic immunofluorescence assay quantified by AQUA® Technology
Authors: Jennifer Bordeaux, Krupa Chandrasekaran, Sue Beruti, Mike Nerenberg, Corinne Ramos, David Rimm, Jelveh Lameh, Naveen Dakappagari
Journal: Cancer Research (2014)

Abstract With the advent of multiple HER-2 targeting agents, the need for a diagnostic test that accurately predicts the levels of HER2 in newly diagnosed breast cancer patients has never been greater. The goal of this study was to develop an immunofluorescence based assay to objectively and reproducibly quantify HER-2 protein level in Formalin-Fixed Paraffin-Embedded (FFPE) specimens using AQUA Technology and to provide a binary readout, thus eliminating reflex testing and enabling quick treatment decisions. Methods: Three well known HER-2 antibody clones, A0485, CB11, and SP3 were evaluated across a three-log dilution series under four different antigen retrieval conditions on a tissue microarray (TMA) containing 80 breast cancer cases with known central HER2 immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) amplification status. The top six immunofluorescence assay combinations out of 108 conditions were quantified by AQUA scoring based on the their ability to accurately separate negative and positive cases using receiver operating characteristic (ROC) analysis. These top six assay conditions were then assessed on an independent TMA containing 94 breast cancer cases and their AQUA scores were compared to HER2 protein levels determined by reverse phase protein microarray (RPMA®), HER2 mRNA levels assessed by RNAscope® as well as to the current “gold standard” IHC and FISH amplification. Results: Top three conditions clearly segregating HER2 positive and HER2 negative breast cancer cases were selected and analyzed on an independent TMA. Conditions associated with both SP3 and A0485 antibodies demonstrated high correlations with both HER2 protein levels determined by RPMA analysis and HER2 mRNA levels assessed by RNAscope (spearman's rho &amp;gt;0.85). Conclusion: Assessment of HER2 status using AQUA Technology was confirmed using two expression platforms, including both protein (RPMA) and RNA (RNAscope) supporting the utilization of the AQUA methodology for diagnostic test development. Citation Format: Jennifer Bordeaux, Krupa Chandrasekaran, Sue Beruti, Mike Nerenberg, Corinne Ramos, David Rimm, Jelveh Lameh, Naveen Dakappagari. Evaluation of HER-2 RNA and protein levels in a large cohort of breast cancer specimens to support development of a diagnostic immunofluorescence assay quantified by AQUA® Technology. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2840. doi:10.1158/1538-7445.AM2014-2840
Genetic variation in nucleotide excision repair (NER) and bladder cancer risk in the Spanish Bladder Cancer Study
Authors: Montserrat Garcia-Closas, Núria Malats, Francisco X. Real, Manolis Kogevinas, Debra Silverman, Adonina Tardon, Consol Serra, Alfredo Carrato, Reina Garcia-Closas, Gemma Castaño-Vinyals, Meredith Yeager, Bob Welch, Stephen Chanock, Mustafa Dosemeci, Nathaniel Rothman
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

2560A 

Background : Nucleotide excision repair (NER) is critical for protecting against damage from chemicals in tobacco smoke, such aromatic amines, which cause bladder cancer. We evaluated the role of genetic variation in NER on bladder cancer risk by analyzing 21 single nucleotide polymorphisms (SNP) in 6 genes primarily involved in this pathway: XPC and RAD23B responsible for damage recognition; helicase ERCC2 ( XPD ); endonucleases ERCC5 ( XPG ) and ERCC1 / ERCC4 ( XPF ); and ERCC6 ( CSB ) involved in coupling NER to the transcription machinery. Methods : Our study population included 1,150 patients with transitional cell carcinoma of the urinary bladder and 1,149 control subjects from five regions in Spain. Information on genotype assays can be found at  . Odds ratios (OR) and 95% confidence intervals (95%CI) were adjusted for age, gender, region and smoking status. Results : Subjects with the Lys/Gln or Gln/Gln genotypes for XPC K939Q (62% of controls) had an increased bladder cancer risk compared to Lys/Lys (OR (95%CI)=1.3 (1.0-1.5), P =0.029). A SNP in intron 5 of RAD23B ( IVS5 -15A>G ) was associated with an increase in risk (OR (95%CI)=1.3 (1.1-1.5), P =0.010, for AG or GG genotype (65% of controls) compared to AA). We found an increase in risk for subjects with the AC or CC genotypes for ERCC2 R156R (71% of controls) compared to AA genotype (OR (95%CI)=1.3 (1.1-1.6), P =0.006), as well as significant haplotype effects in a region of strong LD in ERCC2 (SNPs R156R , D312N , global P = 0.013). Consistent with previous reports, ERCC2 K751Q and D312N were not significantly associated with risk ( P =0.295 and 0.401, respectively). Subjects with the Met/Val or Val/Val genotypes for ERCC5 M254V (7% of controls) had a borderline significant increase in risk compared to Met/Met (OR (95%CI)=1.4 (1.1-2.0), P =0.045). Subjects with the ERCC1 (IVS5+35A>G) AG and GG genotypes had increasing bladder cancer risk compared to AA ( P trend=0.045). The reported ORs were not significantly modified by age, gender or smoking status, except for a larger OR for ERCC2 R156R AC or CC genotypes among never than ever smokers ( P for interaction=0.022). Additional findings, including evaluation of gene-gene interactions and more detailed haplotype analyses, will be presented and interpreted taking into account the number of tests performed and the prior probability of each test. Conclusions : Our results support a previous report of the influence of XPC K939Q on bladder cancer risk, and indicate that variation in RAD23B , ERCC2 , ERCC5 and ERCC2 genes might also be related to risk. Overall, these findings support the role of genetic variation in the NER pathway in bladder cancer etiology.
Principles of Applied Biomedical Instrumentation.
Authors: L. A. Geddes, L. E. Baker
Journal: Annals of Internal Medicine (1975)

Biomedical instruments and the measurement of physiological events resistive transducers inductive transducers capacitive transducers photoelectric transducers piezoelectric devices thermoelectric devices chemical transducers electrodes stimulation and stimulators detection of physiological events by impedance the bioelectric events radiant energy devices ventilation and ventilators criteria for the faithful reproduction of an event.
Original article: Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross‐sectional study
Authors: A. Magnan, J. P. Meunier, C. Saugnac, J. Gasteau, F. Neukirch
Journal: Allergy (2007)

Background: Allergic rhinitis (AR) and asthma are inflammatory conditions of the airways that often occur concomitantly. This observational, cross‐sectional, national study was undertaken to describe the frequency and severity of AR in asthmatic patients. The impact of AR on the quality of life and the therapeutic management of patients in everyday general medical practice were also assessed. Methods: From April to October 2005, 1906 French general practitioners (GP) participated in the study. Each physician had to fill out a questionnaire (including the Juniper Asthma Control Questionnaire and a Rhinitis Questionnaire) for up to 10 consecutive adult asthmatic patients. The first three patients with a confirmed diagnosis of AR (Allergic Rhinitis and its Impact on Asthma classification) were asked to complete the Juniper Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Results: A total of 14 703 patient questionnaires and 4335 auto‐questionnaires were analysed. Patients presented with intermittent (45%), mild (25%), moderate (25%) and severe (4%) persistent asthma. The frequency of AR in asthmatic patients was 55.2% (CI: 95%, 54.4–56.0%). Allergic rhinitis was mild for 54% and moderate/severe for 46% of patients. The frequency and severity of AR increased with the severity of asthma ( P &lt; 0.001). Moreover, AR was associated with worse asthma control whatever be the severity of asthma ( P &lt; 0.001). The global RQLQ scores of AR patients worsened with the severity of asthma ( P &lt; 0.001). Prescription of anti‐asthma treatments significantly increased with the severity of AR. The majority of AR patients (81%) were treated for rhinitis. Conclusions: This survey suggested that AR was associated with more severe asthma, more difficulty to control asthma and substantial impairment of quality of life. The high frequency of AR in asthma patients requires that these conditions should be recognized and managed by GP.
Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual
Authors: IR Peake, MB Liddell, P Moodie, G Standen, DJ Mancuso, EA Tuley, LA Westfield, JM Sorace, JE Sadler, CL Verweij
Journal: Blood (1990)
Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation
Authors: Dhanunjaya Lakkireddy, Yeruva Madhu Reddy, Luigi Di Biase, Subba Reddy Vanga, Pasquale Santangeli, Vijay Swarup, Rhea Pimentel, Moussa C. Mansour, Andre D'Avila, Javier E. Sanchez, J. David Burkhardt, Fadi Chalhoub, Prasant Mohanty, James Coffey, Naushad Shaik, George Monir, Vivek Y. Reddy, Jeremy Ruskin, Andrea Natale
Journal: Journal of the American College of Cardiology (2012)
Abstract 2093: LPP promotes ErbB2 overexpressing breast cancer cell migration, invasion and metastasis
Authors: Elaine Ngan, Peter M. Siegel
Journal: Cancer Research (2014)

Abstract Metastatic breast cancer remains a major hurdle to the successful treatment of this disease. Overexpression of the HER2/ErbB2 receptor tyrosine kinase in breast cancer is associated with metastatic disease and correlates with poor patient prognosis. Growing evidence demonstrates that TGFβ can potentiate ErbB2 signaling to enhance the invasive and metastatic behavior of breast cancer cells. Nonetheless, the mechanisms underlying the synergy between TGFβ and ErbB2 signaling pathways remain to be elucidated. We previously identified Lipoma Preferred Partner (LPP) as an indispensable mediator of TGFβ-induced migration, invasion and focal adhesion turnover of ErbB2-expressing breast cancer cells. Furthermore, we established domains within LPP that are required for its localization to focal adhesions and for its interaction with α-Actinin, an actin cross-linking protein, to promote cell migration and invasion. Herein, we examine the requirement of LPP in tumorigenesis and metastasis formation. We observe that LPP is dispensable for primary tumor growth. Nonetheless, the loss of LPP leads to decrease in spontaneous lung metastasis formation of ErbB2-expressing breast cancer cells injected into the mammary fat pads of mice. Furthermore, we observe that LPP is a critical determinant for efficient dissemination of breast cancer cells. We show that shRNA-mediated reduction of LPP significantly impairs pulmonary metastasis formation in experimental metastasis tail vein assay. Overall, we have identified LPP as a novel mediator that integrates TGFβ and ErbB2 signaling to promote the migration, invasion and metastasis of breast cancer cells. We identify LPP as a pro-metastatic mediator of ErbB2 overexpressing breast cancer cells and a potential new biomarker of metastatic breast cancer. Citation Format: Elaine Ngan, Peter M. Siegel. LPP promotes ErbB2 overexpressing breast cancer cell migration, invasion and metastasis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2093. doi:10.1158/1538-7445.AM2014-2093
Use of a reliable PCR assay for the detection of Neisseria gonorrhoeae in Peruvian patients
Authors: H. Mayta, M. Calderon, J. Taverna, S. Montenegro, J. Balqui, K. Campos, I. Tuero, J. Arevalo, A. Vivar, R.H. Gilman
Journal: Clinical Microbiology and Infection (2006)
PRESCRIPTION OF PHYSICAL MEDICINE BY THE INTERNIST
Authors: A L WATKINS
Journal: Annals of Internal Medicine (1947)

Article1 April 1947PRESCRIPTION OF PHYSICAL MEDICINE BY THE INTERNISTARTHUR L. WATKINS, M.D.ARTHUR L. WATKINS, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-26-4-569 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAdequate and successful use of physical agents can be expected only when they are prescribed in a thoughtful and scientific manner. It is the duty, therefore, of physicians prescribing physical medicine to use similar accuracy and detail as when prescribing drugs. In both instances instructions are given to an intermediary highly skilled in technical matters, but untrained in diagnosis. Full advantage of the physical therapist's technical skill can be obtained only by indicating the nature of the condition to be treated and the specific effects to be expected from therapy. The choice of agents to be used should be determined...Bibliography1. GAMMONSTARR GDI: Studies on the relief of pain by counter-irritation, Jr. Clin. Invest., 1941, xx, 13-20. CrossrefGoogle Scholar2. MAUGHANSMILEY GHDF: Irradiations from quartz-mercury-vapor lamp as factor in control of common cold, Am. Jr. Hyg., 1929, ix, 466-472. Google Scholar3. COLEBROOK D: Irradiation and health. Two experimental studies. Medical Research Council (Great Britain) Spec. Report Series (1929) No. 131, pp. 1-47. Google Scholar4. BLUM HF: Physiological effects of sunlight on man, Physiol. Rev., 1945, xxv, 483-530. CrossrefGoogle Scholar5. BISGARDNYE JDD: Influence of hot and cold applications upon gastric and intestinal motor activity, Surg., Gynec. and Obst., 1940, lxxi, 172-180. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Massachusetts*Presented at the Twenty-Seventh Annual Session, American College of Physicians, Philadelphia, May 16, 1946.From the Department of Physical Medicine, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIntroduction 1 April 1947Volume 26, Issue 4Page: 569-580KeywordsDrugsHospital medicine ePublished: 1 December 2008 Issue Published: 1 April 1947 PDF downloadLoading ...
Industry Support of Researchers in Universities and Academic Medical Centers—Reply
Authors: Hamilton Moses III
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1488: Association between microrna binding site polymorphism and susceptibility to colorectal cancer in Korean population
Authors: Byung Woog Kang, Hyosung Jeon, Yee Soo Chae, Soo Jung Lee, Jong Gwang Kim, Hyunchul Lee, Eun-Jin Lee, Myung Hoon Lee, Jae Yong Park, Gyu Seog Choi, Jun Seok Park
Journal: Cancer Research (2014)

Abstract Background : MicroRNAs (miRNAs) play an important role in the colorectal cancer tumorigenesis by regulation of gene expression through binding to 3′ untranslational region (UTR) of target gene. Single nucleotide polymorphism (SNP) within 3′UTR of gene could be affected by miRNA binding. Docking protein 3 (DOK3) is adapter protein that acts as tumor suppressor through modulating tyrosine kinase signaling. Methods : One hundred thirty five SNPs were selected in Silico analysis for the current study from 3′UTR SNPs of SNP database, which was based on several miRNA database, calculating miRNA bind efficiency on polymorphism, and HapMap database. Here independent two set of study was designed, 380 healthy controls and 371 colorectal adenocarcinoma patients were enrolled in discovery set, and 524 healthy controls and 521 colorectal adenocarcinoma patients were enrolled in replication set. The SNP genotyping was performed using the Sequenom MassARRAY Result: In discovery set, 16 SNPs were significantly associated with colorectal cancer in any genetic model from 135 SNP genotyping. Among 16 SNPs, DOK3 rs2279398G&amp;gt;A was significantly associated in replication set recessive model (adjusted odds ratio (OR) = 0.65, 95% confidence interval (CI) = 0.44-0.97, P = 0.03). In combined analysis, DOK3 rs2279398G&amp;gt;A was associated with significantly decreased risk of colorectal cancer in codominant and recessive model (adjusted OR = 0.84, 95% CI = 0.73-0.96, P = 0.012, adjusted OR = 0.65, CI = 0.49-0.88, P = 0.004, respectively). Conclusion : DOK3 rs2279398G&amp;gt;A may affect the expression of DOK3 by altering miRNA binding efficiency on miRNA-binding sites of the 3′-UTR of DOK3 and impact on colorectal cancer tumorigenesis. This finding suggests that DOK3 rs2279398G&amp;gt;A may be a useful biomarker for determining the susceptibility to colorectal cancer. Citation Format: Byung Woog Kang, Hyosung Jeon, Yee Soo Chae, Soo Jung Lee, Jong Gwang Kim, Hyunchul Lee, Eun-Jin Lee, Myung Hoon Lee, Jae Yong Park, Gyu Seog Choi, Jun Seok Park. Association between microrna binding site polymorphism and susceptibility to colorectal cancer in Korean population. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1488. doi:10.1158/1538-7445.AM2014-1488